FDA Granted Fast Track Status to PureTech Cancer Drug
The monoclonal antibody LYT-200 aims to treat relapsed or refractory high-risk myelodysplastic syndromes.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust pharmaceutical companies to properly prioritize patient safety while expediting new cancer drug development?
The FDA has awarded Fast Track designation to LYT-200, an investigational monoclonal antibody developed by PureTech Health. The treatment is designed for patients with high-risk myelodysplastic syndromes that are relapsed or refractory.
Why it matters
The designation is intended to expedite the development and review process for new drugs that address serious medical conditions with limited treatment options. This regulatory status could help accelerate the timeline for bringing the therapy to market for patients in need.
In a Phase 1b trial, patients receiving a 12 mg/kg dosage of LYT-200 demonstrated an overall response rate of 45.5% and a complete response rate of 27.3%. No dose-limiting toxicities or myeloid suppression were reported during the study.
The players
PureTech Health
This Boston-based biopharmaceutical company focuses on developing novel therapies for serious diseases.
Gallop Oncology
This entity is currently advancing the clinical development and research of the LYT-200 drug candidate.
FDA
The Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and medical devices in the United States.
The details
LYT-200 works as a monoclonal antibody that targets galectin-9 to treat high-risk myelodysplastic syndromes. PureTech Health plans to launch the randomized, double-blind, placebo-controlled STRIDE-MDS Phase 2 trial, which will involve 125 patients administered either 12 mg/kg or 7.5 mg/kg doses.
Timeline
The FDA granted Fast Track designation for LYT-200 in September 2026.
PureTech expects to secure external capital during the first half of 2027.
Deeper Dive
This development follows the standard regulatory pathway established by the FDA Fast Track designation program to expedite the development of drugs for serious unmet medical needs. The move highlights the ongoing evolution of targeted monoclonal antibody therapies in hematologic oncology.
The Fast Track designation could lead to a faster regulatory review, potentially providing patients with earlier access to a new treatment option for high-risk myelodysplastic syndromes. Patients interested in the therapy may look for updates regarding enrollment availability in the upcoming Phase 2 STRIDE-MDS trial.
The takeaway
The FDA designation underscores the potential of targeted therapies in improving outcomes for complex blood disorders. Moving forward, the industry will watch the Phase 2 results to see if the early response rates observed in smaller trials hold up in a larger patient population.
What happens next
PureTech Health intends to secure external capital in the first half of 2027 to support the continued development of LYT-200 through the completion of the Phase 2 trial.
Further reading
For more on the current landscape of oncology research and clinical trials, explore the Cancer section.
Live Poll
Do you trust pharmaceutical companies to properly prioritize patient safety while expediting new cancer drug development?
